Format

Send to

Choose Destination
Eur J Endocrinol. 2008 Sep;159(3):197-202. doi: 10.1530/EJE-08-0289. Epub 2008 Jun 20.

Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones.

Author information

1
Department of Obstetrics and Gynecology, Erlangen University Hospital, Universitaetsstr. 21-23, D-91054 Erlangen, Germany.

Abstract

OBJECTIVE:

To assess the risk of development of hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. Design Description of cases of transsexuals who have developed a hormone-related malignancy observed in their own clinic or reported in the literature. Recommendations for early diagnosis and prevention are presented.

METHODS:

Review of the literature in PubMed.

RESULTS:

In male-to-female transsexuals receiving estrogen administration, lactotroph adenomas, breast cancer, and prostate cancer have been reported. In female-to-male transsexuals receiving treatment with testosterone, a single case of breast carcinoma and several cases of ovarian cancer have been reported. So far endometrial cancer has not been encountered though it remains a potential malignant development.

CONCLUSIONS:

There are so far only a few cases of hormone-related cancer in transsexuals. There may be an underreporting. The probability of a hormone-related tumor increases with the duration of exposure to cross-sex hormones and the aging of the population of transsexuals.

PMID:
18567667
DOI:
10.1530/EJE-08-0289
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Sheridan PubFactory
Loading ...
Support Center